The US will remain the largest VTE market through to 2024.
By Jack Allen, Analyst
10 August 2016
I am an analyst at Datamonitor Healthcare based in the New York office, where I am currently a member of the cardiovascu...
Read full bio
A large and growing population, strong uptake of novel oral anticoagulants (NOACs), and higher reimbursement will mean the US market will remain the biggest and most valuable for the treatment of venous thromboembolism (VTE). Datamonitor Healthcare expects the US VTE market to grow to at a compound annual growth rate (CAGR) of 9.1% over the 10 year forecast period (2015–2024). As in the overall market, growth in the US will be driven by reduced use of generic vitamin K antagonists (VKAs). A moderate yearly price rise will further increase revenue in this market over the forecast period, as compared to Europe, where minimal price rises are expected. The table below shows the sales growth for the NOAC drug class across the US, Japan, and five major EU markets prior to the first patent expirations within this drug class.
Datamonitor Healthcare’s VTE forecast: Datamonitor Healthcare’s VTE forecast covers the anticipated impact of the novel oral anticoagulant drug class on the VTE market.
Get your free demo of Datamonitor Healthcare tody. Simply fill out the form to the right >>>